Using a 15-mer peptide mix, SARS-CoV-2 cross-reactive CD8+ T cells were successfully detected at 75%, 50%, and 56% higher rates in AML, CML, and MM, respectively, compared to those detected using Pep#3(QYI). This evidence concerns the gene CD8A and Miyoshi myopathy.